Athira Pharma’s stock price fell 81% as its lead fosgonimeton treatment for Alzheimer’s disease failed its phase II/III LIFT-AD clinical trial. The drug did not meet the trial’s primary or key secondary endpoints. However, chief medical officer Javier San Martin said Athira planned to continue developing fosgonimeton, citing preliminary results from various subgroups.

Hard-coded credentials found in Moxa industrial security appliances, routers (CVE-2025-6950)
Moxa has fixed 5 vulnerabilities in its industrial network security appliances and routers, including a remotely exploitable flaw (CVE-2025-6950) that may result in complete system